Trials By City
- Advance Clinical Trials
- Albemarle Clinical Trials
- Apex Clinical Trials
- Asheboro Clinical Trials
- Asheville Clinical Trials
- Bayboro Clinical Trials
- Beaufort Clinical Trials
- Belmont Clinical Trials
- Black Mountain Clinical Trials
- Boiling Springs Clinical Trials
- Boone Clinical Trials
- Brevard Clinical Trials
- Bunn Clinical Trials
- Burlington Clinical Trials
- Butner Clinical Trials
- Calabash Clinical Trials
- Camp Lejeune Clinical Trials
- Carrboro Clinical Trials
- Cary Clinical Trials
- Chadbourn Clinical Trials
- Chapel Hill Clinical Trials
- Charlotte Clinical Trials
- Clayton Clinical Trials
- Clemmons Clinical Trials
- Cleveland Clinical Trials
- Clinton Clinical Trials
- Clyde Clinical Trials
- Columbia Clinical Trials
- Columbus Clinical Trials
- Concord Clinical Trials
- Cornelius Clinical Trials
- Davidson Clinical Trials
- Denver Clinical Trials
- Dobson Clinical Trials
- Dunn Clinical Trials
- Durham Clinical Trials
- Eden Clinical Trials
- Elizabeth City Clinical Trials
- Elkin Clinical Trials
- Farmville Clinical Trials
- Fayetteville Clinical Trials
- Flat Rock Clinical Trials
- Fletcher Clinical Trials
- Forest City Clinical Trials
- Fort Bragg Clinical Trials
- Franklin Clinical Trials
- Garner Clinical Trials
- Gastonia Clinical Trials
- Goldsboro Clinical Trials
- Graham Clinical Trials
- Greensboro Clinical Trials
- Greenville Clinical Trials
- Grifton Clinical Trials
- Hamlet Clinical Trials
- Harrisburg Clinical Trials
- Henderson Clinical Trials
- Hendersonville Clinical Trials
- Hickory Clinical Trials
- High Point Clinical Trials
- Hillsborough Clinical Trials
- Holly Springs Clinical Trials
- Hope Mills Clinical Trials
- Hudson Clinical Trials
- Huntersville Clinical Trials
- Jacksonville Clinical Trials
- Kannapolis Clinical Trials
- Kenansville Clinical Trials
- Kernersville Clinical Trials
- King Clinical Trials
- Kinston Clinical Trials
- Knightdale Clinical Trials
- Laurinburg Clinical Trials
- Lenoir Clinical Trials
- Lexington Clinical Trials
- Lincolnton Clinical Trials
- Lumberton Clinical Trials
- Marshall Clinical Trials
- Matthews Clinical Trials
- Mebane Clinical Trials
- Mocksville Clinical Trials
- Moncure Clinical Trials
- Monroe Clinical Trials
- Mooresville Clinical Trials
- Morehead City Clinical Trials
- Morganton Clinical Trials
- Morrisville Clinical Trials
- Mount Airy Clinical Trials
- Mount Pleasant Clinical Trials
- Nashville Clinical Trials
- New Bern Clinical Trials
- Newport Clinical Trials
- North Wilkesboro Clinical Trials
- Oxford Clinical Trials
- Pembroke Clinical Trials
- Pinehurst Clinical Trials
- Pittsboro Clinical Trials
- Pollocksville Clinical Trials
- Raeford Clinical Trials
- Raleigh Clinical Trials
- Reidsville Clinical Trials
- Richlands Clinical Trials
- Robbins Clinical Trials
- Rockingham Clinical Trials
- Rocky Mount Clinical Trials
- Roxboro Clinical Trials
- Rutherford College Clinical Trials
- Rutherfordton Clinical Trials
- Salisbury Clinical Trials
- Sanford Clinical Trials
- Shelby Clinical Trials
- Smithfield Clinical Trials
- Snow Hill Clinical Trials
- Southern Pines Clinical Trials
- Sparta Clinical Trials
- Stanley Clinical Trials
- Statesville Clinical Trials
- Supply Clinical Trials
- Sylva Clinical Trials
- Tabor City Clinical Trials
- Thomasville Clinical Trials
- Trinity Clinical Trials
- Tryon Clinical Trials
- Valdese Clinical Trials
- Wake Forest Clinical Trials
- Warrenton Clinical Trials
- Washington Clinical Trials
- West End Clinical Trials
- Whiteville Clinical Trials
- Williamston Clinical Trials
- Wilmington Clinical Trials
- Wilson Clinical Trials
- Windsor Clinical Trials
- Winston Salem Clinical Trials
- Winterville Clinical Trials
- Winton Clinical Trials
- Yadkinville Clinical Trials
- Yanceyville Clinical Trials
Hickory North Carolina Clinical Trials
Listings Sponsored By:
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of MS who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary [more...] objectives of this study in this study population are to assess the impact of DMF over a 12-month period on patient-reported outcomes (PROs) and health economic-related outcomes and to evaluate additional clinical outcomes at Month 12.
Status: Recruiting Start Date: July 2013 Completion Date: July 2015
The aim of this study is to evaluate the efficacy of the candidate Clostridium difficile (C. difficile) vaccine to prevent primary symptomatic C. difficile infection (CDI) in subjects a risk for CDI where there is a substantial unmet medical need. [more...] Primary objective: - To assess the efficacy of the C. difficile vaccine in preventing the onset of symptomatic primary CDI confirmed by polymerase chain reaction (PCR) in adult subjects aged ≥ 50 years who are at risk for CDI and have received at least 1 injection. Secondary Objectives: Efficacy: - To assess prevention of symptomatic PCR-confirmed primary CDI cases after 3 injections administered at 0, 7, and 30 days - To assess prevention of symptomatic PCR-confirmed primary CDI cases after completion of at least 2 injections. Immunogenicity: - To describe the immunogenicity to toxin A and toxin B in the subset of subjects at specific time points. Safety: - To describe the safety profile of all subjects who receive at least 1 injection.
Status: Recruiting Start Date: July 2013 Completion Date: December 2017
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.
Status: Recruiting Start Date: June 2013 Completion Date:
This randomized, multicenter, double-blind, parallel group study will evaluate the impact of methotrexate discontinuation on the efficacy of subcutaneous RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current methotrexate therapy. [more...] Patients will be initiated on RoActemra/Actemra 162 mg weekly or every 2 weeks, remaining on a stable dose of methotrexate. At Week 24, patients achieving a disease activity score (DAS28) =3.2 will be randomized to either continue receiving a stable dose of methotrexate or to switch to matching placebo until Week 52.
Status: Recruiting Start Date: July 2013 Completion Date: December 2015
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell [more...] lymphoma (DLBCL).
Status: Recruiting Start Date: September 2013 Completion Date: June 2020
This is a non-inferiority study comparing MK-3102 with Sitagliptin in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin therapy. The primary hypothesis is that after 24 weeks, the mean change from baseline in hemoglobin A1c [more...] (A1C) in participants treated with MK-3102 is non-inferior to that in participants treated with sitagliptin. There will be a 2-week run-in period with placebo + metformin prior to the double-blind treatment period.
Status: Recruiting Start Date: June 2013 Completion Date: February 2015
The purpose of this study is to evaluate the efficacy of TAK-875 plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
Status: Recruiting Start Date: June 2013 Completion Date: February 2015
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare FIAsp (faster-acting insulin aspart) to insulin aspart, both in combination with insulin glargine and metformin in adults with type 2 diabetes.
Status: Recruiting Start Date: September 2013 Completion Date: October 2013
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel [more...] (or prasugrel or ticagrelor).
Status: Recruiting Start Date: May 2013 Completion Date: December 2015
The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes mellitus with inadequate control despite [more...] treatment with diet and exercise. The safety and tolerability of canagliflozin will also be assessed.
Status: Recruiting Start Date: June 2013 Completion Date: December 2014
This is a non-randomized, open label, two-cohort, multi-institutional study to evaluate the use of diarrheal management tools intended to facilitate timely intervention and treatment modifications due to afatinib treatment-related diarrhea in patients with EGFR mutations-positive adenocarcinoma of the lung. [more...] Patients in Cohort 1 will follow diarrhea management. Patients in Cohort 2 will receive prophylactic loperamide starting the fist day of afatinib treatment.
Status: Recruiting Start Date: April 2013 Completion Date: February 2015
The primary hypothesis is that additional LDL-C lowering with AMG 145 when used in addition to other treatment for dyslipidemia is well tolerated and decreases the risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary [more...] revascularization in subjects with clinically evident cardiovascular disease
Status: Recruiting Start Date: January 2013 Completion Date: February 2018
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
Status: Recruiting Start Date: January 2013 Completion Date: December 2013
To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5
Status: Recruiting Start Date: May 2013 Completion Date: August 2021
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
Status: Recruiting Start Date: December 2012 Completion Date: October 2015
This study is being carried out to see if dapagliflozin when added to a patients current anti-diabetes therapy is effective in reducing cardiovascular events such as myocardial infarction (MI) (heart attack), ischemic stroke, and cardiovascular (CV) related death, [more...] compared with placebo (inactive study medication).
Status: Recruiting Start Date: April 2013 Completion Date: April 2019
In this study, the investigational products are naproxen, a non-steroidal antiinflammatory drug (NSAID), and loratadine, an anti-histamine. Both agents are being investigated as prophylactic medications to reduce the incidence and/or severity of bone pain in breast cancer subjects receiving [more...] adjuvant or neoadjuvant myelosuppressive chemotherapy and pegfilgrastim prophylaxis.
Status: Recruiting Start Date: November 2012 Completion Date: August 2014
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod 0.6 mg/day or 1.2mg/day in subjects with RRMS.
Status: Recruiting Start Date: February 2013 Completion Date: June 2018
The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
Status: Recruiting Start Date: October 2012 Completion Date: January 2016
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects [more...] with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab Pfizer program.
Status: Recruiting Start Date: August 2012 Completion Date: August 2015
The purpose of this study is to evaluate long-term performance of the DF4 Connector System. This evaluation is based on the number of DF4 lead related complications occurring during the study compared to the number of leads enrolled in the study. The DF4 [more...] systems will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the DF4 Connector systems. This study is part of the Product Performance Platform (PPP).
Status: Recruiting Start Date: November 2011 Completion Date: January 2019
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy, [more...] tolerability, and safety of GEn at lower doses (450 and 300 mg/day) as well as the already approved dose of 600 mg/day versus placebo for the treatment of subjects with moderate to severe primary RLS. This study is being conducted as a post-marketing commitment (PMC) as a condition of the approval of HORIZANT tablets (NDA 022399).
Status: Recruiting Start Date: June 2012 Completion Date: August 2014
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
Status: Recruiting Start Date: June 2012 Completion Date: December 2018
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
Status: Recruiting Start Date: June 2012 Completion Date: August 2014
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC). Patients will be [more...] randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and platinum (carboplatin/cisplatin) iv on Day 1 of each 21-day cycle. Patients who have not progressed after 4 cycles will continue with either onartuzumab (MetMAb) or placebo as maintenance therapy until disease progression or unacceptable toxicity occurs.
Status: Recruiting Start Date: April 2012 Completion Date: June 2015
Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Participants often receive the best healthcare available for their condition.
Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. Trials are federally regulated with strict guidelines to protect participants.
Hickory North Carolina Clinical Trials Information presented on ClinicalTrialsSearch.org is not intended to be a substitute for qualified medical advice visit or treatment with a real physician. We are not physicians. Always consult with a medical doctor (MD). ClinicalTrialsSearch.org is a website dedicated to listing clinical research studies in human subjects, including those specifically related to Hickory North Carolina. Clinical research trials and medical trials take place in hundreds of cities across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectiveness of new treatments and drugs. The purpose of the studies is to answer specific human health questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions. Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Many times the participants receive treatment for free, and sometimes they are paid for their time. Participants often receive the best healthcare available possible for their condition. Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. U.S. - based Hickory North Carolina studies are federally regulated with strict guidelines to protect patients.
There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.
There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.
Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.